Lecture to focus on engineering strategies applied to design safe and efficacious bispecific drug candidates, utilizing our proprietary platform technologiesSEATTLE,…
Complete Survival of Animals Lethally Infected into Lungs with RSV Achieved Upon NV-387 Oral Treatment SHELTON, CT / ACCESSWIRE /…
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the…
SHELTON, CT / ACCESSWIRE / May 10, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum…
Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after…
Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after…
NV-387 Possesses Strong Orthopoxvirus Activity Relevant to Both Sexual and Inhalation Modes of Transmission, Says NanoViricides SHELTON, CT / ACCESSWIRE…
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc.…
NV-387 Possesses Strong Anti-Influenza-A Virus Activity, and May Have Activity Against H5N1 Bird Flu Virus, Says NanoViricides SHELTON, CT /…
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June…